Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire has sued Roxane Laboratories and Watson Laboratories in connection with the violation of Vyvanse patents.
Subscribe to our email newsletter
Vyvanse is a prescription medicine which is used to treat attention deficit hyperactivity disorder (ADHD) in adults and in children who are at least 6 years old.
Shire has filed a case against Roxane in the US District Court for the District of New Jersey and against Watson in the US District Court for the Central District of California.
The lawsuit was filed in connection with the submission of abbreviated new drug applications (ANDAs) by Roxane and Watson seeking marketing approval for the generic versions of almost all approved doses of Vyvanse with the US Food and Drug Administration (FDA).